Histone Deacetylase Inhibitors
-
Subject Areas on Research
-
A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.
-
A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors.
-
A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.
-
A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.
-
ARID1A-mutated ovarian cancers depend on HDAC6 activity.
-
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
-
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
-
An overview of naturally occurring histone deacetylase inhibitors.
-
Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
-
Antidepressant actions of histone deacetylase inhibitors.
-
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
-
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.
-
Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment.
-
Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma.
-
Cyclophilin A and Ess1 interact with and regulate silencing by the Sin3-Rpd3 histone deacetylase.
-
Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases.
-
Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation.
-
Discovery of a fluorescent probe with HDAC6 selective inhibition.
-
Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells.
-
Epigenetic activation of unintegrated HIV-1 genomes by gut-associated short chain fatty acids and its implications for HIV infection.
-
Epigenetic therapy for solid tumors: from bench science to clinical trials.
-
Evaluation of class I HDAC isoform selectivity of largazole analogues.
-
Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
-
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.
-
FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function.
-
Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms.
-
Glucose metabolism as a target of histone deacetylase inhibitors.
-
HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.
-
HDAC6 modulates cell motility by altering the acetylation level of cortactin.
-
HDACs in skeletal muscle remodeling and neuromuscular disease.
-
Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer.
-
Histone Deacetylase 7 Inhibition in a Murine Model of Gram-Negative Pneumonia-Induced Acute Lung Injury.
-
Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors.
-
Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
-
Histone Deacetylases (HDACs) in Gastric Cancer: An Update of their Emerging Prognostic and Therapeutic Role.
-
Histone deacetylase 3 binds to and regulates the GCMa transcription factor.
-
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
-
Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective.
-
Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.
-
Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo.
-
Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death.
-
Largazole pharmacokinetics in rats by LC-MS/MS.
-
Largazole: from discovery to broad-spectrum therapy.
-
Latency reversal and viral clearance to cure HIV-1.
-
Lipids Reprogram Metabolism to Become a Major Carbon Source for Histone Acetylation.
-
Loss of betaglycan expression in ovarian cancer: role in motility and invasion.
-
Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors.
-
Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial.
-
Mechanism-Based Inhibitors of the Human Sirtuin 5 Deacylase: Structure-Activity Relationship, Biostructural, and Kinetic Insight.
-
Methods for the analysis of histone H3 and H4 acetylation in blood.
-
Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors.
-
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer.
-
Panobinostat for the management of multiple myeloma.
-
Phase 2 study of sodium phenylbutyrate in ALS.
-
Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.
-
Phosphorus-based SAHA analogues as histone deacetylase inhibitors.
-
Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.
-
Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives.
-
QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature.
-
Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation.
-
Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
-
Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.
-
Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation.
-
Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition.
-
Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor.
-
Synthesis and activity of largazole analogues with linker and macrocycle modification
-
Synthesis and biological evaluation of largazole zinc-binding group analogs.
-
Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).
-
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
-
The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity.
-
The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.
-
The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.
-
The discovery of histone deacetylase.
-
The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways.
-
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
-
Timing of valproic acid in acute lung injury: prevention is the best therapy?
-
Total synthesis and molecular target of largazole, a histone deacetylase inhibitor.
-
Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
-
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
-
Keywords of People